SCHEMBL817445

SCHEMBL817445

OCC(O)COc1cccc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.60
MAPK1 P28482 1/20 0.60
KDM4E B2RXH2 2/20 0.50
PRMT5 O14744 1/20 0.49
WDR77 Q9BQA1 1/20 0.49
MAOB P27338 1/20 0.49
AOC3 Q16853 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
SCN1A P35498 1/20 0.46
SCN5A Q14524 1/20 0.46
SCN9A Q15858 1/20 0.46
HIF1A Q16665 1/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
AR P10275 1/20 0.44
IDH2 P48735 1/20 0.44
FGFR1 P11362 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16414719 1.00 TSHR (0.60) TSHRMAPK1KDM4EPRMT5WDR77
SCHEMBL16414613 1.00 TSHR (0.60) TSHRMAPK1KDM4EPRMT5WDR77
SCHEMBL4047162 0.88 L3MBTL1 (0.54) TSHRMAPK1KDM4EPRMT5WDR77
SCHEMBL5575173 0.86 KDM4E (0.49) TSHRMAPK1KDM4EPRMT5WDR77
SCHEMBL7952233 0.86 SCN1A (0.50) TSHRMAPK1KDM4EPRMT5WDR77
SCHEMBL11613592 0.86 KDM4E (0.49) TSHRMAPK1KDM4EPRMT5WDR77
SCHEMBL773252 0.86 MAOB (0.55) KDM4EPRMT5WDR77MAOBAOC3
SCHEMBL24015832 0.85 KDM4E (0.46) TSHRMAPK1KDM4EPRMT5WDR77
SCHEMBL13761630 0.84 TSHR (0.65) TSHRMAPK1KDM4EL3MBTL1HIF1A
SCHEMBL13155078 0.84 TSHR (0.65) TSHRMAPK1KDM4EL3MBTL1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031898-A1 PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES INSTYTUT FARMACEUTYCZNY (PL) 2015-01-29 US disclosed
EP-2274266-B1 PROCESS FOR THE PREPARATION OF PROSTAGLANDIN ANALOGUES AND INTERMEDIATES THEREOF SCINOPHARM TAIWAN LTD (TW) 2014-10-15 EP disclosed
US-8742143-B2 Process for the preparation of prostaglandin analogues SCINOPHARM TAIWAN, LTD. (TW) 2014-06-03 US disclosed
US-8742143-B2 Process for the preparation of prostaglandin analogues SCINOPHARM TAIWAN, LTD. (TW) 2014-06-03 US disclosed
US-20130211128-A1 Process for the Preparation of Prostaglandin Analogues SCINOPHARM TAIWAN LTD. (TW) 2013-08-15 US disclosed
US-20130211128-A1 Process for the Preparation of Prostaglandin Analogues SCINOPHARM TAIWAN LTD. (TW) 2013-08-15 US disclosed
US-8436194-B2 Process for the preparation of prostaglandin analogues and intermediates thereof SCINOPHARM TAIWAN, LTD. (TW) 2013-05-07 US disclosed
US-20110130577-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof SCINOPHARM TAIWAN LTD. 2011-06-02 US disclosed
US-20110130577-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof SCINOPHARM TAIWAN LTD. 2011-06-02 US disclosed
US-7897795-B2 Process for the preparation of prostaglandin analogues and intermediates thereof SCINOPHARM TAIWAN LTD. (TW) 2011-03-01 US disclosed
US-7897795-B2 Process for the preparation of prostaglandin analogues and intermediates thereof SCINOPHARM TAIWAN LTD. (TW) 2011-03-01 US disclosed
WO-2009141718-A2 PROCESS FOR THE PREPARATION OF PROSTAGLANDIN ANALOGUES AND INTERMEDIATES THEREOF SCINOPHARM TAIWAN LTD. (TW) 2009-11-26 WO disclosed
US-20090259058-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof SCINOPHARM TAIWAN LTD. 2009-10-15 US disclosed
US-20090259058-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof SCINOPHARM TAIWAN LTD. 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259058-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof PTGIS, PTGES, PTGER1 TSHR 1742/4885MAPK1 1318/4885KDM4E 4422/4885
US-20150031898-A1 PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES PTGES, PTGIS, PTGES2 TSHR 2046/4885MAPK1 2140/4885KDM4E 2909/4885
US-20110130577-A1 Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof PTGIS, PTGES, PTGER1 TSHR 1742/4885MAPK1 1318/4885KDM4E 4422/4885
US-20130211128-A1 Process for the Preparation of Prostaglandin Analogues PTGIS, PTGES, PTGER1 TSHR 883/4885MAPK1 2014/4885KDM4E 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.